Sign In
Alnylam Pharmaceuticals Inc (ALNY)
SHARE
Email Confirmation
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME
Overview
News
People
Financials
Company Information
Overview
A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.
News Feeds
-
Movers roundup: Textron, American Greetings
AP
Dec 23 2008
-
Alnylam shares rise on prospect for clinical trial
AP
Dec 23 2008
Press Releases
-
Alnylam to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference Jan-07-2009, 04:00PM EST
-
Alnylam Advances RNAi Therapeutics Pipeline and Files Company's First Systemic Delivery IND Dec-23-2008, 08:00AM EST
-
Alnylam Publishes Pre-Clinical Research on Direct CNS Delivery of RNAi Therapeutics Dec-19-2008, 08:00AM EST
-
Alnylam Pharmaceuticals and Roche Collaboration Selected as Best Partnership Alliance by Scrip Dec-11-2008, 08:00AM EST
News From Around the Web
News
-
The IN VIVO Blog Selects First Annual 'Deal of the Year'
(Genetic Engineering News)Jan 08 2009 -
Tekmira expects to get $11.2 million payment ... (Canadian Business Online)Jan 08 2009
-
Jan 08 2009
-
Tekmira Announces $11.2 Million 3-Year Manufacturing and Development Commitment From Partner Alnylam (Genetic Engineering News)Jan 08 2009
-
Jan 08 2009
-
1 Comment (MIT Technology Review)Jan 05 2009
-
Alnylam files IND application for liver cancer drug (WallSt.net)Dec 26 2008
-
Alnylan teams up with the University of California (Boston Globe)Dec 10 2008
-
Good for iPods, but bad for patients (Boston Globe)Dec 10 2008
Employees
Number of Employees: 129
Revenue per Employee: $324,967
Financials
Quarterly
Annual
| Income Statement | 11/2008 | 08/2008 | 05/2008 | 02/2008 |
|---|---|---|---|---|
| Sales | NA | NA | NA | NA |
| Gross Operating Profit | 25.73 Mil. | 23.83 Mil. | 22.19 Mil. | 18.23 Mil. |
| Operating Income before D & A (EBITDA) | -3.23 Mil. | -12.83 Mil. | -3.96 Mil. | -2.89 Mil. |
| Total Income Before Interest Expenses (EBIT) | -3.48 Mil. | -11.3 Mil. | -802 K. | 1.97 Mil. |
| Total Net Income | -2.86 Mil. | -12.76 Mil. | -1.24 Mil. | 1.66 Mil. |
| Basic EPS, Total | -0.07 | -0.31 | -0.03 | 0.04 |
| Diluted EPS, Total | -0.07 | -0.31 | -0.03 | 0.04 |
| BALANCE STATEMENT | 11/2008 | 08/2008 | 05/2008 | 02/2008 |
|---|---|---|---|---|
| Cash and Equivalents | 520.16 Mil. | 538.32 Mil. | 443.87 Mil. | 455.6 Mil. |
| Total Assets | NA | 547.63 Mil. | NA | 463.56 Mil. |
| Total Liabilities | NA | NA | 26.09 Mil. | 289.12 Mil. |
| Total Capitalization | 204.56 Mil. | 200.11 Mil. | 204.77 Mil. | 199.17 Mil. |
| Cash Flow | 11/2008 | 08/2008 | 05/2008 | 02/2008 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | NA | NA | NA | NA |
| Net Cash From Investing Activities | NA | NA | NA | NA |
| Net Cash From Financing Activities | NA | NA | NA | NA |
| Net Change in Cash & Cash Equivalents | NA | NA | NA | NA |
| Income Statement | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Sales | NA | -3.82 Mil. | -3.12 Mil. | -2.44 Mil. |
| Gross Operating Profit | 50.9 Mil. | 30.74 Mil. | 8.84 Mil. | 6.72 Mil. |
| Operating Income before D & A (EBITDA) | -93.18 Mil. | -35.69 Mil. | -40.35 Mil. | -29.82 Mil. |
| Total Income Before Interest Expenses (EBIT) | -79.14 Mil. | -33.58 Mil. | -41.94 Mil. | -31.99 Mil. |
| Total Net Income | -85.47 Mil. | -34.61 Mil. | -42.91 Mil. | -32.65 Mil. |
| Basic EPS, Total | -2.21 | -1.09 | -1.96 | -2.98 |
| Diluted EPS, Total | -2.21 | -1.09 | -1.96 | -2.98 |
| BALANCE STATEMENT | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Cash and Equivalents | 455.6 Mil. | 127.96 Mil. | 15.76 Mil. | 20.27 Mil. |
| Total Assets | 463.56 Mil. | 222.78 Mil. | 82.41 Mil. | 48.18 Mil. |
| Total Liabilities | 289.12 Mil. | 22.92 Mil. | 18.48 Mil. | 6.58 Mil. |
| Total Capitalization | 199.17 Mil. | 207.09 Mil. | 67.3 Mil. | 52.55 Mil. |
| Cash Flow | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | NA | -24.63 Mil. | -16.48 Mil. | -19.57 Mil. |
| Net Cash From Investing Activities | NA | -30.05 Mil. | -40.42 Mil. | -34.6 Mil. |
| Net Cash From Financing Activities | NA | 166.63 Mil. | 52.62 Mil. | 50.98 Mil. |
| Net Change in Cash & Cash Equivalents | NA | 112.2 Mil. | -4.52 Mil. | -2.92 Mil. |
Company Profile Change Request
The data provided in our company profiles comes from third party information providers.- To request a change please click here
Also in Portfolio.com
Most Read
Most Emailed
Recently Commented
TOP 5
(Daily)
A smart take on the top stories shaping the business world.
Executives & Careers
(Tuesdays)
A weekly guide to the personalities and ideas that are transforming the business world.
Inside Portfolio.com
(Wednesdays)
Our roundup of the week's best from Portfolio.com.
Culture & Lifestyle
(Fridays)
A weekly guide to the best ways to spend your time - and money.
In This Issue
(Monthly)
Be the first to know when the latest issue of Condé Nast Portfolio magazine is online.
RSS Most Read
Mobile